“…Primary and metastatic SCNECs are characterized by a smaller cell size, although scattered large cells can be found. Since RCC is the most common recipient of tumor-to-tumor metastasis, it may occur that NE carcinomas from other sites may metastasize to renal primaries (80), including angiomyolipoma (81); in such a case, the differential diagnosis with a primary mixed NEC can be challenging in the absence of proper clinical information. As for their bladder counterpart, there is no standard of care for renal HGNEC; effective disease control may be achieved through surgery, platinum-based chemotherapy, and radiotherapy (75) in order to delay the occurrence of metastatic tumors.…”
Large cell neuroendocrine carcinoma (LCNEC)of the urinary tract is a high-grade neuroendocrine tumor with distinct pathological features, usually portending an aggressive clinical behavior in comparison to conventional urothelial carcinoma. Due to its low prevalence, little is known about its clinical management and there is no current standard of care. The aim of this review was to summarize the current knowledge about LCNEC of the bladder, ureter and kidney, with relevance to diagnostic, prognostic and therapeutic issues, through a systematic analysis of clinical, pathological and outcome data retrieved from the literature.
“…Primary and metastatic SCNECs are characterized by a smaller cell size, although scattered large cells can be found. Since RCC is the most common recipient of tumor-to-tumor metastasis, it may occur that NE carcinomas from other sites may metastasize to renal primaries (80), including angiomyolipoma (81); in such a case, the differential diagnosis with a primary mixed NEC can be challenging in the absence of proper clinical information. As for their bladder counterpart, there is no standard of care for renal HGNEC; effective disease control may be achieved through surgery, platinum-based chemotherapy, and radiotherapy (75) in order to delay the occurrence of metastatic tumors.…”
Large cell neuroendocrine carcinoma (LCNEC)of the urinary tract is a high-grade neuroendocrine tumor with distinct pathological features, usually portending an aggressive clinical behavior in comparison to conventional urothelial carcinoma. Due to its low prevalence, little is known about its clinical management and there is no current standard of care. The aim of this review was to summarize the current knowledge about LCNEC of the bladder, ureter and kidney, with relevance to diagnostic, prognostic and therapeutic issues, through a systematic analysis of clinical, pathological and outcome data retrieved from the literature.
“…Mastectomy was performed in nearly all cases. Information on the outcome of the reported cases was not available in all of the cases but palliative therapy determined the outcome [1, 8–12].…”
Section: Resultsmentioning
confidence: 99%
“…[12]443DuctalT2N0M1no++−20%RCC, liver, mediastinumAfter 3 months disease progression—further treatment was refusedUlamec et al. [8]060Ductal a T4N2M13++−22%RCCWithout recurrence for 18 monthsPerrin et al. [9]049DuctalT4N1M13−−−NoRCC, lung and boneNot specifiedPresent case079Ductal bilateralRight: T2N3M13+++80%RCC and boneDeath 3 years after diagnosis by multimorbidityLeft: T2N0M12+++70% Interval C–M interval between breast cancer diagnosis and metastasis to RCC, G grading, ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, Ki 67 proliferation marker, RCC clear cell renal cell carcinoma, + positive, − negative, no no further information, TNM classification of tumor, lymphe nodes, metastasis a With neuroendocrine differentiation…”
SummaryBackgroundCancer-to-cancer metastasis is very rare with less than 50 cases described in literature. This article reports a case of breast cancer with synchronous metastasis to clear cell renal cell cancer.Case descriptionA 79-year-old woman was diagnosed with a bilateral breast carcinoma. Sonographic staging investigation of the abdomen revealed a 6 cm wide expansion of the right kidney. Bilateral mastectomy and nephrectomy of the right kidney was performed. The histology revealed a clear cell renal cell carcinoma and in the center of the tumor a 0.5 cm metastasis of the breast cancer. The patient’s comorbidities and performance status precluded chemotherapy und she received palliative radiotherapy, targeted monoclonal antibody therapy and antihormonal treatment.ConclusionsEven if cancer-to-cancer metastasis is a very rare phenomenon, the simultaneous or consecutive finding of a renal tumor in women with breast cancer should be carefully evaluated.
“…In the cases of mixed neuroendocrine and other types of tumors we should be aware of the possibility of tumorto-tumor metastasis. These cases are rare; however, renal cell carcinoma is the most common recipient of tumorto-tumor metastasis in malignant tumors [24]. Moreover, metastases of neuroendocrine carcinoma were described into other types of renal tumors such as angiomyolipoma [25].…”
We report a case of a 56-year-old male with a primary large cell neuroendocrine renal carcinoma. Grossly, the left kidney was enlarged by a solid tumor that measured 145 x 125 x 100 mm. Histologically, the tumor consisted of large cells with a moderate to abundant amount of eosinophilic cytoplasm. The nuclei were irregular, some of them with finely or coarsely granular chromatin, others with vesicular chromatin and prominent nucleoli. The tumor cells showed multiple mitotic figures (up to 32 mitoses/10 HPF). In some areas, the tumor cells were arranged in solid sheets; however, the predominant pattern was solid-alveolar, trabecular and cribriform. Large areas of tumor necrosis were found. Immunohistochemically, the tumor cells were positive for synaptophysin, CD56 and CD57. Cytokeratin AE1/AE3, vimentin and CD10 were positive only focally. Chromogranin showed weak cytoplasmic positivity in rare tumor cells. Cytokeratin CAM5.2, cytokeratin 34betaE12, BerEP 4, EMA, TTF-1, cytokeratin 7, cytokeratin 20, calretinin, serotonin, somatostatin, gastrin, calcitonin, glukagon and insulin were negative. Primary large cell neuroendocrine carcinoma of the kidney is a rare tumor. To the best of our knowledge, only 3 cases of a tumor of this type have been reported to date.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.